Payment overview · 2025
General Payments
$329.28
15 reported records · 7 companies
Healthcare provider profile · identity verified
Dan Argin Boggus, MD
Allopathic & Osteopathic Physicians|Family Medicine · TAVARES, FL · NPI 1669419248
Verified facts
What the public records show
CMS Open Payments records show Dan Argin Boggus, MD received $329.28 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.93 | 29.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.69 | 23.3% | 3 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $44.77 | 13.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.33 | 12.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.74 | 8.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.13 | 7.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.69 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.28 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $96.93 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $96.93 | 5 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $44.77 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.33 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 237 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
237 | 66 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
72 | 70 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 871 | 276 |
| Lisinopril | Lisinopril | 659 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 624 | 176 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 478 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 132 |
| Losartan Potassium | Losartan Potassium | 346 | 115 |
| Meloxicam | Meloxicam | 287 | 82 |
| Omeprazole | Omeprazole | 277 | 89 |
| Simvastatin | Simvastatin | 272 | 88 |
| Metformin Hcl | Metformin Hcl | 265 | 85 |
| Sertraline Hcl | Sertraline Hcl | 264 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 249 | 77 |
| Eliquis | Apixaban | 237 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 70 |
| Gabapentin | Gabapentin | 220 | 81 |
| Montelukast Sodium | Montelukast Sodium | 219 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 72 |
| Methylprednisolone | Methylprednisolone | 197 | 136 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 54 |
| Tramadol Hcl | Tramadol Hcl | 169 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 59 |
| Furosemide | Furosemide | 157 | 58 |
| Allopurinol | Allopurinol | 147 | 45 |
| Ezetimibe | Ezetimibe | 143 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 61 |
| Alendronate Sodium | Alendronate Sodium | 124 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 124 | 50 |
| Potassium Chloride | Potassium Chloride | 120 | 40 |
| Metformin Hcl Er | Metformin Hcl | 118 | 37 |
| Celecoxib | Celecoxib | 111 | 42 |
| Azithromycin | Azithromycin | 106 | 92 |
| Trazodone Hcl | Trazodone Hcl | 106 | 31 |
| Carvedilol | Carvedilol | 98 | 40 |
| Alprazolam | Alprazolam | 95 | 32 |
| Famotidine | Famotidine | 91 | 32 |
| Atenolol | Atenolol | 90 | 25 |
| Lorazepam | Lorazepam | 85 | 31 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 81 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 81 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 30 |
| Glipizide | Glipizide | 79 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 28 |
| Chlorthalidone | Chlorthalidone | 75 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 74 | 51 |
| Glipizide Er | Glipizide | 73 | 25 |
| Paxlovid | Nirmatrelvir/Ritonavir | 72 | 70 |
| Folic Acid | Folic Acid | 68 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 13 |
| Spironolactone | Spironolactone | 61 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 20 |
| Ozempic | Semaglutide | 58 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 23 |
| Glimepiride | Glimepiride | 57 | 22 |
| Clonazepam | Clonazepam | 56 | 11 |
| Prednisone | Prednisone | 56 | 24 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 12 |
| Fenofibrate | Fenofibrate | 51 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 14 |
| Bupropion Xl | Bupropion Hcl | 44 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 36 |
| Estradiol | Estradiol | 43 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 14 |
| Sotalol | Sotalol Hcl | 43 | 14 |
| Bumetanide | Bumetanide | 42 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 42 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 11 |
| Pregabalin | Pregabalin | 41 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 34 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 16 |
| Nitroglycerin | Nitroglycerin | 38 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 19 |
| Finasteride | Finasteride | 37 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 21 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 36 | 16 |
| Novolin N | Insulin Nph Human Isophane | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 35 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 14 |
| Temazepam | Temazepam | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Jantoven | Warfarin Sodium | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 28 | 28 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | 11 |
| Digoxin | Digoxin | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | 14 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 12 |
| Cephalexin | Cephalexin | 23 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 16 |
| Fluconazole | Fluconazole | 19 | 14 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 13 |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.28 · 15 records | PFIZER INC. | CAPVAXIVE, ELIQUIS, FARXIGA, NEFFY, NURTEC ODT, OTEZLA, Ozempic, REPATHA, The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error